{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:37:45Z","timestamp":1765233465194,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Copenhagen"},{"name":"van Andel Research Institut"},{"name":"NovoNordisk Foundation"},{"name":"Independent research fund Denmark"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Venetoclax, a BCL-2 inhibitor, has proven to be effective in several hematological malignancies, including mantle cell lymphoma (MCL). However, development of venetoclax resistance is inevitable and understanding its underlying molecular mechanisms can optimize treatment response. We performed a thorough genetic, epigenetic and transcriptomic analysis of venetoclax-sensitive and resistant MCL cell lines, also evaluating the role of the stromal microenvironment using human and murine co-cultures. In our model, venetoclax resistance was associated with abrogated TP53 activity through an acquired mutation and transcriptional downregulation leading to a diminished apoptotic response. Venetoclax-resistant cells also exhibited an upregulation of the PI3K\/Akt pathway, and pharmacological inhibition of Akt and ERK with TIC-10 led to cell death in all venetoclax-resistant cell lines. Overall, we highlight the importance of targeted therapies, such as TIC-10, against venetoclax resistance-related pathways, which might represent future therapeutic prospects.<\/jats:p>","DOI":"10.3390\/cancers15020510","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T04:31:32Z","timestamp":1673843492000},"page":"510","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Agnete Marie","family":"Granau","sequence":"first","affiliation":[{"name":"Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 1165 Copenhagen, Denmark"},{"name":"Rigshospitalet, Department of Hematology, University Hospital Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar Aar\u00f8e","family":"Andersen","sequence":"additional","affiliation":[{"name":"Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 1165 Copenhagen, Denmark"},{"name":"Rigshospitalet, Department of Hematology, University Hospital Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Taouxi","sequence":"additional","affiliation":[{"name":"Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 1165 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6931-5287","authenticated-orcid":false,"given":"Nawar","family":"Dalila","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Department of Clinical Biochemistry, University Hospital Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanne Bay","family":"Mogensen","sequence":"additional","affiliation":[{"name":"Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 1165 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5980-7939","authenticated-orcid":false,"given":"Lasse Sommer","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-9601","authenticated-orcid":false,"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 1165 Copenhagen, Denmark"},{"name":"Rigshospitalet, Department of Hematology, University Hospital Copenhagen, 2100 Copenhagen, Denmark"},{"name":"Novo Nordisk Foundation Center for Stem Cell Biology, DanStem, Faculty of Health Sciences, University of Copenhagen, 1165 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-500X","authenticated-orcid":false,"given":"Konstantinos","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Biotech Research and Innovation Centre (BRIC), University of Copenhagen, 1165 Copenhagen, Denmark"},{"name":"Rigshospitalet, Department of Clinical Biochemistry, University Hospital Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"739441","DOI":"10.3389\/fonc.2021.739441","article-title":"Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas","volume":"11","author":"Sethi","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2020","journal-title":"Hemasphere"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11523-018-0560-7","article-title":"Targeting BCL-2 in Hematologic Malignancies","volume":"13","author":"Khan","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/aol.2019.03.02","article-title":"Venetoclax for the treatment of mantle cell lymphoma","volume":"3","author":"Lin","year":"2019","journal-title":"Ann. Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1080\/10428194.2018.1457148","article-title":"Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: Implications for design of clinical trials","volume":"59","author":"Agarwal","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Erratum: Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1182\/bloodadvances.2020003944","article-title":"Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL","volume":"5","author":"Jayappa","year":"2021","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14251","article-title":"BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma","volume":"179","author":"Dousset","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)\u2014Outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12157","article-title":"Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner","volume":"12","author":"Dimopoulos","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ymeth.2013.04.006","article-title":"BH3 profiling in whole cells by fluorimeter or FACS","volume":"61","author":"Ryan","year":"2013","journal-title":"Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1158\/0008-5472.CAN-15-2622","article-title":"Identification of DNA Methylation\u2013Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma","volume":"76","author":"Becket","year":"2016","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/bioinformatics\/btw691","article-title":"Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi","volume":"33","author":"Fortin","year":"2017","journal-title":"Bioinformatics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gdata.2016.05.012","article-title":"Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip","volume":"9","author":"McCartney","year":"2016","journal-title":"Genom. Data"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Liu","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1\u2013mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-11-1440","article-title":"Tipping the Noxa\/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia","volume":"18","author":"Tromp","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1593-12","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: A promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1073\/pnas.0700020104","article-title":"The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage","volume":"104","author":"Wang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","first-page":"1102","article-title":"PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma","volume":"12","author":"Huang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/08977191003745472","article-title":"IGFBP-2 expression in MCF-7 cells is regulated by the PI3K\/AKT\/mTOR pathway through Sp1-induced increase in transcription","volume":"28","author":"Mireuta","year":"2010","journal-title":"Growth Factors"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ghir.2015.03.003","article-title":"Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes","volume":"25","author":"Wilhelm","year":"2015","journal-title":"Growth Horm. IGF Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.leukres.2011.08.006","article-title":"High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia","volume":"35","author":"Kaiser","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"171ra17","DOI":"10.1126\/scitranslmed.3004828","article-title":"Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects","volume":"5","author":"Allen","year":"2013","journal-title":"Sci. Transl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/510\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:45Z","timestamp":1760119545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15020510"],"URL":"https:\/\/doi.org\/10.3390\/cancers15020510","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}